Redeye updates on Embracer following weak Q1-results and lowered guidance for 2025/26E. While we reduce our 2025/26E significantly (adjusted EBIT down 45%) on the back of the updated guidance, the company’s pipeline looks strong over the next years, suggesting improved growth and earnings in 2026/27-27/28E.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/